This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A stable pharmaceutical composition of 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolate, comprising 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolic acid or a pharmaceutically acceptable salt of 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolic acid and citrate, and has a pH of 7.5 to 10.5.

2. (Previously Presented) A stable pharmaceutical composition according to claim 1, further comprising an additional pharmaceutically acceptable active ingredient or an adjuvant.

3. (Previously Presented) A pharmaceutical composition according to claim 2, wherein the adjuvant is formaldehyde.

4. (Previously Presented) A pharmaceutical composition according to claim 2, wherein the additional active ingredient is folate.

5. (Previously Presented) A pharmaceutical composition according to claim 4, wherein the folate is tetrahydrofolic acid or a salt thereof.

6. (Previously Presented) A pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable salt of 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolic acid is a calcium or an acidic salt thereof.

7. (Previously Presented) A pharmaceutical composition according to claim 2, wherein the additional active ingredient is a cytostatic agent.

8. (Previously Presented) A pharmaceutical composition according to claim 2, wherein the additional active ingredient is a fluorinated pyrimidine compound.

9. (Previously Presented) A pharmaceutical composition according to

claim 8, wherein the fluorinated pyrimidine compound is a 5-fluoruracil or a 5-fluoruracil compound.

10. (Previously Presented) A pharmaceutical composition according to claim1, additionally comprising at least one antioxidant or a radical scavenger.

11. (Previously Presented) A pharmaceutical composition according to claim 10, wherein the antioxidant or radical scavenger is vitamin C or reduced glutathione.

12. (Previously Presented) A pharmaceutical composition according to claim 1, which is in the form of a lyophilisate, dry powder or dry mixture.

13. (Previously Presented) A pharmaceutical composition according to claim 1, which is in the form of a lyophilisation solution.

14. (Previously Presented) A method of stabilizing a composition comprising 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolate according to claim 1, comprising treating 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolic acid with citrate and bringing it to a pH of 7.5 to 10.5.

15. (Previously Presented) A method of preparing a composition according to claim 1 comprising bringing together a pharmaceutically acceptable salt of 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolic acid and citrate at a pH of 7.5 to 10.5.

16. (Previously Presented) A pharmaceutical composition according to claim 1, which has a pH of 8.5 to 9.5.

17. (Previously Presented) A pharmaceutical composition according to claim 8, wherein the fluorinated pyrimidine compound is a capecitabine (xeloda).

18. (Withdrawn) A method for treating a solid tumor, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 1.

19. (Currently Amended) A pharmaceutical composition according to claim 1, which has a pH of greater than 8.5 to up to 9.5.

20. (Previously Presented) A pharmaceutical composition according to claim 1, which is in the form of a lyophilisate.

21. (Previously Presented) A stable pharmaceutical composition of 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolate, comprising 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolic acid or a pharmaceutically acceptable salt of 5,10-methylene-(6R)-, -(6S)-or -(6R,S)-tetrahydrofolic acid and citrate, and has a pH of 7.5 to 10.5, which stable pharmaceutical composition is present without the exclusion of atmospheric oxygen.

22. (Previously Presented) A pharmaceutical composition according to claim 21, which does not contain a reducing agent.

23. (Previously Presented) A method according to claim 15, which is performed without the exclusion of atmospheric oxygen.

24. (Previously Presented) A method according to claim 15, which is performed without the addition of a reducing agent to the composition.